

# OHMR Research Ethics and Governance Metrics Program



## Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 1 2023  
01/01/2023 – 31/03/2023

**NSW Office for Health and Medical Research**



## Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

## Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

## Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Change benchmark to/measure/Total Time/rather than time spent with LHD Research Office alone
- Number of Greater than Low Risk projects (GLR) processed within application total time
  - 90 days for ethics, 60 days for governance
  - Threshold changes
    - >75% = Performing
    - 55%-75% = Underperforming
    - <55% = Not performing



## Ethics Review Timelines of Human Research in NSW PHOs

### KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

**NSW State Benchmark:** The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

#### Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

#### Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

#### Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

#### Selection Criteria Summary:

<b>Scope</b>	Human Research Ethics Applications
<b>Frequency</b>	Quarterly
<b>Inclusions</b>	<ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = Approved/ Approved with conditions within the reporting period</li> </ul>
<b>Exclusions</b>	<ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Approval Type = Not within the reporting period</li> <li>Migrated studies</li> </ul>

#### Total

Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

### Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 1 2023**) are shown in **Table 1**.

During the reporting period, 225 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 65 days. Of these 225 studies, 79 (35%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

**Table 1.** The 90 calendar days benchmark for approval of human research ethics applications (**greater than low risk**) during the reporting period.

<b>Ethics Approval (Q1 2023)</b>							
<b>All greater than low risk applications</b>							
<b>NSW PHOs</b>	<b>Total Number of Applications</b>	<b>Total Time 90 Day Benchmark</b>			<b>Total Time Breakdown (calendar days)</b>		<b>Count Request for Information</b>
		<b>Count &lt; 90 Day Benchmark</b>	<b>% &lt; 90 Day Total Time Benchmark</b>	<b>Average Total Time (Days)</b>	<b>Average Research Office Time</b>	<b>Average Researcher Time</b>	
BLLBRRY	23	22	96%	44	27	19	1.3
CINSW	3	2	67%	66	45	21	2.0
HNELHD	32	32	100%	37	16	22	1.1
ISLHD	0	0	-	-	-	-	-
JHFMHN	3	3	100%	73	35	38	1.7
NBMLHD	4	4	100%	71	51	20	1.3
NNSWLHD	3	2	67%	53	21	32	2.0
NSLHD	14	4	29%	122	68	54	2.1
SCHN	11	10	91%	62	36	25	1.5
SESLHD	22	20	91%	70	44	26	2.2
SLHD-CCD	5	5	100%	63	19	44	2.0
SLHD-RPA	33	32	97%	53	20	33	1.2
SVHN	28	21	75%	78	37	41	2.1
SWSLHD	20	17	85%	54	34	20	1.5
WNSWLHD	4	2	50%	272	58	214	2.3
WSLHD	20	20	100%	64	39	25	1.5
<b>TOTAL</b>	<b>225</b>	<b>196</b>	<b>87%</b>	<b>65</b>	<b>34</b>	<b>32</b>	<b>1.6</b>

**Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.**

<b>Ethics Approval (Q1 2023)</b>							
<b>Clinical Trials</b>							
<b>NSW PHOs</b>	<b>Total Number of Applications</b>	<b>Total Time 90 Day Benchmark</b>			<b>Total Time Breakdown (calendar days)</b>		<b>Count Request for Information</b>
		<b>Count &lt; 90 Day Benchmark</b>	<b>% &lt; 90 Day Total Time Benchmark</b>	<b>Average Total Time (Days)</b>	<b>Average Research Office Time</b>	<b>Average Researcher Time</b>	
		BLLBRRY	23	22	96%	44	
CINSW	0	0	-	-	-	-	-
HNELHD	4	4	100%	43	16	27	1.0
ISLHD	0	0	-	-	-	-	-
NSLHD	6	0	0%	138	82	56	2.3
SCHN	5	5	100%	58	34	24	1.4
SESLHD	3	3	100%	61	37	24	2.3
SLHD-CCD	2	2	100%	56	15	41	2.0
SLHD-RPA	12	12	100%	62	24	38	1.4
SVHN	11	8	73%	86	39	48	2.3
SWSLHD	2	1	50%	79	40	39	1.5
WNSWLHD	1	1	100%	31	24	7	1.0
WSLHD	8	8	100%	66	41	26	1.8
<b>TOTAL</b>	<b>79</b>	<b>68</b>	<b>86%</b>	<b>65</b>	<b>37</b>	<b>32</b>	<b>1.6</b>

**Table 3.** Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
<b>BLLBRRY</b>	1	-	75	22	27	43	0	-	-
<b>CINSW</b>	0	-	-	0	-	-	0	-	-
<b>HNELHD</b>	0	-	-	1	12	29	3	17	47
<b>ISLHD</b>	0	-	-	0	-	-	0	-	-
<b>NSLHD</b>	0	-	-	4	75	126	2	95	163
<b>SCHN</b>	0	-	-	4	40	63	1	12	39
<b>SESLHD</b>	0	-	-	1	40	89	2	36	47
<b>SLHD-CCD</b>	1	20	79	1	10	33	0	-	-
<b>SLHD-RPA</b>	3	34	74	0	-	-	9	21	58
<b>SVHN</b>	4	47	116	4	34	57	3	33	86
<b>SWSLHD</b>	0	-	-	1	37	61	1	43	96
<b>WNSWLHD</b>	0	-	-	0	-	-	1	24	31
<b>WSLHD</b>	1	42	61	7	40	67	0	-	-
<b>Grand Total</b>	<b>11</b>	<b>39</b>	<b>89</b>	<b>45</b>	<b>42</b>	<b>58</b>	<b>23</b>	<b>31</b>	<b>69</b>

**Table 4.** Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/07/2023 and 31/03/2023), **by sponsor type**

	Q3 2022			Q4 2022			Q1 2023		
<b>Sponsor Type</b>	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
<b>Collaborative Group</b>	11	32	71	9	28	50	11	39	89
<b>Commercial Entity</b>	35	28	93	29	34	67	45	42	58
<b>Investigator Initiated</b>	35	27	60	28	30	69	23	31	69
<b>Total</b>	<b>81</b>	<b>28</b>	<b>76</b>	<b>66</b>	<b>32</b>	<b>65</b>	<b>79</b>	<b>37</b>	<b>65</b>

**Table 5. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/07/2022 and 31/03/2023).**

NSW PHOs	Q3 2022							Q4 2022							Q1 2023						
	Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	22	20	91%	26	19	86%	50	15	11	73%	46	11	73%	73	23	20	87%	19	22	96%	44
CINSW	8	4	50%	46	6	75%	198	9	9	100%	10	9	100%	42	3	3	100%	21	2	67%	66
HNELHD	26	26	100%	19	25	96%	42	29	29	100%	14	29	100%	31	32	30	94%	22	32	100%	37
ISLHD	3	2	67%	45	3	100%	53	2	2	100%	15	2	100%	50	0	0	-	-	0	-	-
JHFMHN	6	1	17%	71	3	50%	136	4	3	75%	54	3	75%	100	3	3	100%	38	3	100%	73
NBMLHD	4	2	50%	46	4	100%	65	8	8	100%	19	8	100%	54	4	4	100%	20	4	100%	71
NNSWLHD	3	1	33%	50	1	33%	92	1	1	100%	6	1	100%	37	3	2	67%	32	2	67%	53
NSLHD	12	5	42%	45	9	75%	76	8	6	75%	47	6	75%	91	14	9	64%	54	4	29%	122
SCHN	9	8	89%	28	7	78%	52	13	11	85%	20	12	92%	43	11	9	82%	25	10	91%	62
SESLHD	15	13	87%	32	14	93%	71	21	21	100%	15	20	95%	59	22	19	86%	26	20	91%	70
SLHD-CCD	9	8	89%	26	9	100%	64	8	3	38%	45	8	100%	66	5	3	60%	44	5	100%	63
SLHD-RPA	43	43	100%	16	43	100%	40	40	38	95%	23	40	100%	43	33	24	73%	33	32	97%	53
SVHN	19	13	68%	41	16	84%	64	27	21	78%	51	21	78%	83	28	21	75%	41	21	75%	78
SWSLHD	15	12	80%	30	8	53%	125	20	18	90%	23	20	100%	50	20	18	90%	20	17	85%	54
WNSWLHD	4	2	50%	45	3	75%	78	5	5	100%	15	4	80%	44	4	2	50%	214	2	50%	272
WSLHD	22	9	41%	47	18	82%	143	17	16	94%	22	14	82%	70	20	16	80%	25	20	100%	64
<b>TOTAL</b>	<b>220</b>	<b>169</b>	<b>77%</b>	<b>32</b>	<b>188</b>	<b>85%</b>	<b>75</b>	<b>227</b>	<b>202</b>	<b>89%</b>	<b>27</b>	<b>208</b>	<b>92%</b>	<b>56</b>	<b>225</b>	<b>183</b>	<b>81%</b>	<b>32</b>	<b>196</b>	<b>87%</b>	<b>65</b>



## Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days									
<p><b>NSW State Benchmark:</b> The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days</p>									
<p><b>Definition:</b> The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.</p> <p><b>Context:</b> The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.</p> <p><b>Desired Outcome:</b> Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.</p>	<p><b>Selection Criteria Summary:</b></p> <table border="1"> <tr> <td><b>Scope</b></td> <td>Site-specific assessment (SSA) applications</td> </tr> <tr> <td><b>Frequency</b></td> <td>Quarterly</td> </tr> <tr> <td><b>Inclusions</b></td> <td> <ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = “Authorised” or “authorised with conditions” within the reporting period</li> </ul> </td> </tr> <tr> <td><b>Exclusions</b></td> <td> <ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Migrated studies</li> </ul> </td> </tr> </table> <p><b>Total Time:</b> Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.</p>	<b>Scope</b>	Site-specific assessment (SSA) applications	<b>Frequency</b>	Quarterly	<b>Inclusions</b>	<ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = “Authorised” or “authorised with conditions” within the reporting period</li> </ul>	<b>Exclusions</b>	<ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Migrated studies</li> </ul>
<b>Scope</b>	Site-specific assessment (SSA) applications								
<b>Frequency</b>	Quarterly								
<b>Inclusions</b>	<ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = “Authorised” or “authorised with conditions” within the reporting period</li> </ul>								
<b>Exclusions</b>	<ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Migrated studies</li> </ul>								

**Summary:**

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 1 2023**) are shown in **Table 6**. During the reporting period, **436** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **46** days. Of these **436** studies, **212** were classified as clinical trials (**Table 7**). Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

**Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q1 2023)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
Calvary	9	7	78%	39	16	3	4	16
CCLHD	8	8	100%	13	4	6	0	4
FWLHD	1	1	100%	15	8	0	0	8
HNELHD	38	34	89%	36	12	8	2	12
ISLHD	15	15	100%	3	1	1	0	1
JHFMHN	1	1	100%	28	28	0	0	28
MLHD	2	2	100%	5	3	3	0	3
MNCLHD	8	8	100%	23	12	5	2	12
NBMLHD	7	7	100%	42	21	12	3	21
NNSWLHD	6	6	100%	29	12	7	5	12
NSLHD	29	16	55%	71	36	13	1	36
NSWHPTH	3	2	67%	70	11	30	0	11
SCHN	18	9	50%	109	10	43	0	10
SESLHD	51	39	76%	42	14	9	1	14
SLHD-CCD	22	22	100%	19	1	6	5	1
SLHD-RPA	67	67	100%	28	5	9	3	5
SNSWLHD	3	3	100%	45	27	18	0	27
SVHN	32	19	59%	67	11	9	0	11
SWSLHD	43	33	77%	62	16	10	1	16
WNSWLHD	13	11	85%	51	5	44	0	5
WSLHD	60	44	73%	55	16	14	3	16
<b>TOTAL</b>	<b>436</b>	<b>354</b>	<b>81%</b>	<b>46</b>	<b>13</b>	<b>12</b>	<b>2</b>	<b>13</b>

**Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q1 2023) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	7	6	86%	32	17	2	5	17
CCLHD	2	2	100%	19	6	3	0	6
FWLHD	1	1	100%	15	8	0	0	8
HNELHD	13	12	92%	39	16	16	2	16
ISLHD	4	4	100%	4	2	1	0	2
JHFMHN	0	0	-	-	-	-	-	-
MLHD	1	1	100%	3	3	0	0	3
MNCLHD	6	6	100%	25	15	4	2	15
NBMLHD	5	5	100%	49	22	16	4	22
NNSWLHD	4	4	100%	33	11	9	6	11
NSLHD	14	8	57%	65	29	13	1	29
NSWHPTH	0	0	-	-	-	-	-	-
SCHN	11	8	73%	62	8	20	0	8
SESLHD	15	9	60%	46	14	15	1	14
SLHD-CCD	15	15	100%	23	1	7	6	1
SLHD-RPA	35	35	100%	36	5	13	4	5
SNSWLHD	1	1	100%	50	30	20	0	30
SVHN	18	14	78%	48	10	7	0	10
SWSLHD	20	16	80%	67	16	12	0	16
WNSWLHD	2	2	100%	8	4	4	0	4
WSLHD	38	28	74%	44	16	14	3	16
<b>TOTAL</b>	<b>212</b>	<b>177</b>	<b>83%</b>	<b>43</b>	<b>12</b>	<b>12</b>	<b>2</b>	<b>12</b>

**Table 8.** NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	2	18	19	4	20	43	1	7	13
CCLHD	0	-	-	0	-	-	2	6	19
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	3	25	48	5	15	24	5	11	50
ISLHD	0	-	-	2	2	5	2	2	4
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	1	3	3
MNCLHD	1	12	17	2	8	12	3	20	37
NBMLHD	1	7	45	3	26	48	1	24	55
NNSWLHD	1	23	27	1	2	44	2	9	31
NSLHD	4	23	101	9	31	50	1	45	63
NSWHPTH	0	-	-	0	-	-	0	-	-
SCHN	3	11	42	6	9	55	2	4	115
SESLHD	10	15	47	4	12	35	1	5	87
SLHD-CCD	5	0	20	7	1	21	3	0	32
SLHD-RPA	3	1	22	14	3	31	18	8	42
SNSWLHD	1	30	50	0	-	-	0	-	-
SVHN	1	6	45	13	9	32	4	13	100
SWSLHD	5	14	159	9	11	31	6	26	46
WNSWLHD	0	-	-	1	5	8	1	3	8
WSLHD	1	41	95	25	16	33	12	13	63
<b>Total</b>	<b>42</b>	<b>14</b>	<b>58</b>	<b>105</b>	<b>12</b>	<b>34</b>	<b>65</b>	<b>12</b>	<b>50</b>

**Table 9.** Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q3 2022			Q4 2022			Q1 2023		
<b>Sponsor Type</b>	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
<b>Collaborative Group</b>	49	7	43	38	11	42	42	14	58
<b>Commercial Entity</b>	118	10	37	94	9	26	105	12	34
<b>Investigator Initiated</b>	70	8	48	70	14	51	65	12	50
<b>Total</b>	<b>237</b>	<b>9</b>	<b>42</b>	<b>202</b>	<b>11</b>	<b>38</b>	<b>212</b>	<b>12</b>	<b>43</b>

**Table 10.** Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods ( between 01/07/2022 and 31/03/2023).

LHD	Q3 2022						Q4 2022						Q1 2023								
	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	1	0	0	26	1	100%	29	0	0	-	-	0	-	-
CALVARY	10	9	90%	5	10	100%	10	11	9	82%	13	10	91%	20	9	4	44%	16	7	78%	39
CCLHD	7	7	100%	4	7	100%	27	10	10	100%	3	10	100%	19	8	8	100%	4	8	100%	13
FWLHD	2	1	50%	13	1	50%	80	0	0	-	-	0	-	-	1	1	100%	8	1	100%	15
HNELHD	32	29	91%	9	31	97%	27	43	27	63%	12	42	98%	31	38	26	68%	12	34	89%	36
ISLHD	19	19	100%	2	18	95%	11	13	13	100%	2	13	100%	9	15	15	100%	1	15	100%	3
JHFMHN	2	1	50%	30	2	100%	33	2	0	0	22	2	100%	26	1	0	0	28	1	100%	28
MLHD	5	4	80%	11	5	100%	28	3	3	100%	6	3	100%	7	2	2	100%	3	2	100%	5
MNCLHD	5	5	100%	6	5	100%	30	6	4	67%	15	6	100%	34	8	6	75%	12	8	100%	23
NBMLHD	15	8	53%	24	12	80%	54	23	10	43%	16	23	100%	35	7	1	14%	21	7	100%	42
NNSWLHD	7	5	71%	9	7	100%	17	2	1	50%	16	2	100%	22	6	3	50%	12	6	100%	29
NSLHD	35	11	31%	28	25	71%	57	27	14	52%	15	21	78%	47	29	7	24%	36	16	55%	71
NSWHPH	9	4	44%	15	7	78%	57	11	6	55%	15	5	45%	69	3	2	67%	11	2	67%	70
SCHN	36	31	86%	8	26	72%	76	32	28	88%	8	21	66%	57	18	14	78%	10	9	50%	109
SESLHD	47	38	81%	9	41	87%	35	53	45	85%	10	40	75%	40	51	32	63%	14	39	76%	42
SLHD-CCD	22	22	100%	2	22	100%	24	26	25	96%	3	26	100%	23	22	22	100%	1	22	100%	19
SLHD-RPA	70	60	86%	6	63	90%	27	57	51	89%	5	57	100%	20	67	62	93%	5	67	100%	28
SNSWLHD	0	0	-	-	0	-	-	2	0	0%	77	0	0%	84	3	1	33%	27	3	100%	45
SVHN	29	24	83%	9	18	62%	55	20	19	95%	7	17	85%	37	32	21	66%	11	19	59%	67
SWSLHD	61	60	98%	6	46	75%	66	50	34	68%	12	39	78%	51	43	21	49%	16	33	77%	62
WNSWLHD	11	9	82%	6	11	100%	16	6	5	83%	7	5	83%	33	13	12	92%	5	11	85%	51
WSLHD	64	63	98%	6	57	89%	29	40	36	90%	9	33	83%	40	60	33	55%	16	44	73%	55
<b>Total</b>	<b>488</b>	<b>410</b>	<b>84%</b>	<b>9</b>	<b>414</b>	<b>85%</b>	<b>40</b>	<b>438</b>	<b>340</b>	<b>78%</b>	<b>10</b>	<b>376</b>	<b>86%</b>	<b>37</b>	<b>436</b>	<b>293</b>	<b>67%</b>	<b>13</b>	<b>351</b>	<b>81%</b>	<b>46</b>

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

**James Cokayne**

**Principal Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9391 9920](tel:(02)93919920) | [james.cokayne@health.nsw.gov.au](mailto:james.cokayne@health.nsw.gov.au)

**Yagiz Aksoy**

**Senior Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9461 7887](tel:(02)94617887) | [yagiz.aksoy@health.nsw.gov.au](mailto:yagiz.aksoy@health.nsw.gov.au)

**Jackie Nie**

**Policy Officer and Data Analyst**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9391 9854](tel:(02)93919854) | [Jackie.nie@health.nsw.gov.au](mailto:Jackie.nie@health.nsw.gov.au)